Pain Management

  • Recofol
  • Sufentanil
  • Ruituoxi
  • AF102
  • Gastroenterology

  • Lactéol Fort
  • Oral Rehydration Salts
  • Nephrology

  • Phosmin
  • FC818
  • Luolinping
  • Calcitriol
  • M8
  • NKF201
  • NKF202
  • Oncology

  • 801
  • AD1
  • Consumer Health

  • Xiexinshu SR
  • High-C
  • C+
  • AD1

    Product: AD1 injection
    Indication: Treatment for various cancers
    Status: Preclinical

    AD1 is a novel Colchicine derivative, with Colchicine’s anti-tumor properties but with 150 times lower toxicity.


    Colchicine is a toxic extract derived from Autumn Crocus and African Climbing Lily, of the genus Colchicum. Commonly prescribed as a treatment for acute gout, acute gouty arthritis, and familial Mediterranean fever, Colchicine’s anti-tumor properties are also well-documented.

    Colchicine binds to tubulin and inhibits microtubule polymerization, preventing cancer cell mitosis. However, such so-called "colchicine poisoning" also affects normal cells, and can cause abdominal pain, nausea, vomiting, bone marrow depression, anorexia, and hepatotoxicity. Therefore, colchicine’s chemotherapeutic value is limited.


    AD1, currently in preclinical development, is a novel Colchicine derivative that preserves Colchine’s efficacy against cancer cells, but with 150 times lower toxicity against normal cells.

        PUMC Pharmaceutical Co., Ltd.